

# Robert Weinkove

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8926475/publications.pdf>

Version: 2024-02-01

61  
papers

2,287  
citations

304368

22  
h-index

223531

46  
g-index

62  
all docs

62  
docs citations

62  
times ranked

3134  
citing authors

#	ARTICLE	IF	CITATIONS
1	Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. <i>New England Journal of Medicine</i> , 2019, 380, 2225-2236.	13.9	599
2	Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2020, 21, 1188-1200.	5.1	208
3	Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. <i>Clinical and Translational Immunology</i> , 2019, 8, e1049.	1.7	205
4	Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014. <i>Internal Medicine Journal</i> , 2014, 44, 1283-1297.	0.5	108
5	Venetoclax and obinutuzumab in chronic lymphocytic leukemia. <i>Blood</i> , 2017, 129, 2702-2705.	0.6	108
6	Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. <i>Medical Journal of Australia</i> , 2020, 212, 481-489.	0.8	107
7	Fibrinogen concentrate for acquired hypofibrinogenaemic states. <i>Transfusion Medicine</i> , 2008, 18, 151-157.	0.5	103
8	Non-Invasive Detection of Anaemia Using Digital Photographs of the Conjunctiva. <i>PLoS ONE</i> , 2016, 11, e0153286.	1.1	70
9	NKT cell-dependent glycolipid-peptide vaccines with potent anti-tumour activity. <i>Chemical Science</i> , 2015, 6, 5120-5127.	3.7	64
10	Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial. <i>British Journal of Haematology</i> , 2020, 189, 279-290.	1.2	56
11	A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and $\alpha$ -galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 285-298.	2.0	49
12	Vaccination with Irradiated Tumor Cells Pulsed with an Adjuvant That Stimulates NKT Cells Is an Effective Treatment for Glioma. <i>Clinical Cancer Research</i> , 2012, 18, 6446-6459.	3.2	47
13	Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic. <i>Internal Medicine Journal</i> , 2020, 50, 667-679.	0.5	37
14	Low-dose thalidomide in myelofibrosis. <i>Haematologica</i> , 2008, 93, 1100-1101.	1.7	35
15	Techniques for predicting a favourable response to renal angioplasty in patients with renovascular disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2001, 10, 799-805.	1.0	32
16	Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapy. <i>Haematologica</i> , 2013, 98, 376-384.	1.7	32
17	T-cell intrinsic Toll-like receptor signaling: implications for cancer immunotherapy and CAR T-cells. , 2021, 9, e003065.		30
18	Engaging Natural Killer T Cells as "Universal Helpers"™ for Vaccination. <i>Drugs</i> , 2017, 77, 1-15.	4.9	29

#	ARTICLE	IF	CITATIONS
19	Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE). <i>BMJ Open</i> , 2020, 10, e034629.	0.8	26
20	IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells. <i>Leukemia</i> , 2021, 35, 1380-1391.	3.3	26
21	Species-specific Activity of Glycolipid Ligands for Invariant NKT Cells. <i>ChemBioChem</i> , 2012, 13, 1349-1356.	1.3	25
22	Chimeric antigen receptor T-cell therapies: Optimising the dose. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1678-1689.	1.1	25
23	An autologous leukemia cell vaccine prevents murine acute leukemia relapse after cytarabine treatment. <i>Blood</i> , 2014, 124, 2953-2963.	0.6	24
24	Glycolipid-peptide conjugate vaccines enhance CD8+ T cell responses against human viral proteins. <i>Scientific Reports</i> , 2017, 7, 14273.	1.6	24
25	Red cell transfusion thresholds in myelodysplastic syndromes: a clinician survey to inform future clinical trials. <i>Internal Medicine Journal</i> , 2017, 47, 695-698.	0.5	18
26	Invariant natural killer T cells and asthma: Immunologic reality or methodologic artifact?. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 882-885.	1.5	17
27	Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions. <i>Blood</i> , 2015, 126, 496-496.	0.6	17
28	COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement. <i>Internal Medicine Journal</i> , 2021, 51, 763-768.	0.5	12
29	Glycolipid-peptide conjugate vaccines elicit CD8 <sup>+</sup> T-cell responses and prevent breast cancer metastasis. <i>Clinical and Translational Immunology</i> , 2022, 11, .	1.7	12
30	An empirical test of the biodiversity hypothesis: Exposure to plant diversity is associated with a reduced risk of childhood acute lymphoblastic leukemia. <i>Science of the Total Environment</i> , 2021, 768, 144627.	3.9	11
31	Association between early peak temperature and mortality in neutropenic sepsis. <i>Annals of Hematology</i> , 2015, 94, 857-864.	0.8	10
32	Enhancing T cell responses and tumour immunity by vaccination with peptides conjugated to a weak NKT cell agonist. <i>Organic and Biomolecular Chemistry</i> , 2019, 17, 1225-1237.	1.5	10
33	Vaccines adjuvanted with an NKT cell agonist induce effective T-cell responses in models of CNS lymphoma. <i>Immunotherapy</i> , 2020, 12, 395-406.	1.0	10
34	Imipenem versus piperacillin/tazobactam for empiric treatment of neutropenic fever in adults. <i>Internal Medicine Journal</i> , 2013, 43, 1151-1154.	0.5	9
35	Managing hypogammaglobulinaemia secondary to haematological malignancies in Australia and New Zealand: a clinician survey. <i>Internal Medicine Journal</i> , 2019, 49, 358-363.	0.5	9
36	Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323). <i>Blood</i> , 2016, 128, 2054-2054.	0.6	8

#	ARTICLE	IF	CITATIONS
37	Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial. <i>Leukemia and Lymphoma</i> , 2022, 63, 304-314.	0.6	8
38	Zidovudine-induced pure red cell aplasia presenting after 4 years of therapy. <i>Aids</i> , 2005, 19, 2046-2047.	1.0	7
39	Mucosal-Associated Invariant T (MAIT) Cell Dysfunction and PD-1 Expression in Prostate Cancer: Implications for Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 748741.	2.2	7
40	Innate-like T cell profile in myeloma: Severe deficiency of $\gamma\delta$ T cells in aminobisphosphonate-treated patients. <i>Leukemia and Lymphoma</i> , 2016, 57, 977-980.	0.6	6
41	Immunity without innate lymphoid cells. <i>Nature Immunology</i> , 2016, 17, 1237-1238.	7.0	6
42	A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LL1 trial. <i>British Journal of Haematology</i> , 2021, 194, 298-308.	1.2	6
43	Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study. <i>Blood</i> , 2018, 132, 459-459.	0.6	6
44	Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study. <i>Blood</i> , 2019, 134, 2926-2926.	0.6	5
45	Human induced-T-to-natural killer cells have potent anti-tumour activities. <i>Biomarker Research</i> , 2022, 10, 13.	2.8	4
46	Fever and pancytopenia in a patient with Crohn's disease. <i>Gut</i> , 2013, 62, 1327-1327.	6.1	3
47	Flow Cytometric Analysis of Mechanically Disaggregated Bone Marrow Trepine Biopsies. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 935-940.	0.7	3
48	A randomized controlled feasibility trial of paracetamol during febrile neutropenia in hemato-oncology patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 1540-1547.	0.6	3
49	Temperature management in haematology patients with febrile neutropenia: a practice survey. <i>New Zealand Medical Journal</i> , 2013, 126, 62-73.	0.5	3
50	B-cell prolymphocytic leukaemia with a t(4;14) FGFR3/IGH translocation: response to ibrutinib. <i>Pathology</i> , 2020, 52, 491-492.	0.3	2
51	An adjuvanted whole cell vaccine as post-remission immunotherapy for acute leukemia. <i>OncImmunity</i> , 2015, 4, e995568.	2.1	1
52	Temporal changes in neutropenic blood culture isolates and disease associations: a single centre series of 1139 episodes. <i>Internal Medicine Journal</i> , 2017, 47, 962-965.	0.5	1
53	Maintaining a fit T cell compartment: lymphoma treatment sequencing in the era of chimeric antigen receptor T cell therapies. <i>Internal Medicine Journal</i> , 2019, 49, 1338-1338.	0.5	1
54	PB1892 REAL WORLD TREATMENT PERSISTENCE OF NEW ZEALAND IBRUTINIB CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS IN A NAMED PATIENT PROGRAM. <i>HemaSphere</i> , 2019, 3, 861-862.	1.2	1

#	ARTICLE	IF	CITATIONS
55	Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 676-683.	0.6	1
56	Efficient depletion of chronic lymphocytic leukemia B cells using serial rounds of immunomagnetic depletion. <i>Journal of Immunological Methods</i> , 2013, 396, 152-156.	0.6	0
57	FIXED-DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES. <i>Hematological Oncology</i> , 2019, 37, 82-84.	0.8	0
58	THIRD GENERATION CAR T-CELL THERAPY UTILISING TOLL LIKE RECEPTOR 2 CO-STIMULATION. <i>Hematological Oncology</i> , 2019, 37, 517-517.	0.8	0
59	Anticoagulants: current and future therapeutic options. , 2008, , 65-90.		0
60	Abstract B103: Altering the mevalonate pathway to enhance CD8+ T-cell responses. , 2019, , .		0
61	Chimeric antigen receptor T-cells in New Zealand: challenges and opportunities. <i>New Zealand Medical Journal</i> , 2021, 134, 96-108.	0.5	0